Relationship between RRM1 expression in non small-cell lung cancer tissue and gemcitabine-containing regimen resistance

Aim:To explore the relationship between the expression of RRM1 in non small-cell lung cancer(NSCLC) tissue and gemcitabine-containing regimen resistance.Methods:A total of 108 cases of NSCLC were allocated into 2 groups:54 cases were treated with gemcitabine and cisplatin(GP group),54 cases were treated with paclitaxel and cisplatin (TP group).All patients had received 2 cycles chemotherapy,and 21 days was a cycle.The expression of RRM1 in 108 cases of NSCLC tissue was detected by immunohistochemistry method and the relationship between the RRM1 expression and gemcitabin-containing regimen resistance was analyzed.Results:The high expression of RRM1 was associated with GP regimen resistance in NSCLC.The high expression rate of RRM1 in chemoresistant group was 62.5%,that of chemosensitive group was 30.0%,and the difference was significant(χ2=5.704,P=0.017).The high expression of RRM1 was not associated with TP regimen resistance in NSCLC(χ2=0.557,P=0.456).Conclusion:The high expression of RRM1 in NSCLC is related to gemcitabine-containing regimen resistance.